MED MEDIFAST INC Insider Trading

Medifast director Scott Schlackman acquires 5,000 shares in two tranches as stock trades well below its 52-week high amid unprofitable fundamentals.

Director Scott Schlackman purchased 5,000 shares over two trading days in early May at prices near current levels, adding to two prior open-market purchases he made in 2023. The stock is currently trading roughly 18% below its 52-week high and has risen modestly over the past three months, yet the company remains unprofitable despite significant recent revenue expansion. Schlackman's prior purchases in 2023 are too recent to evaluate their timing outcomes, but this repeat buying at depressed valuation levels adds conviction to his earlier accumulation. The pattern of a director buying into weakness while the company operates at a loss suggests either confidence in an inflection point or positioning for longer-term recovery; however, without recent earnings results or visibility into near-term profitability, this trade enters a fundamentally challenged environment.

MED Chairman & CEO Chard buys 17.7K shares at $10.11; stock down -35.9% from 52-week high amid -36.0% revenue decline and unprofitability

Chard Daniel R, Chairman & CEO of MEDIFAST INC, purchased 17,678 shares at $10.11 on 2026-03-20, boosting his holdings to 188,233 shares (+10.4% vs pre-transaction). The purchase occurs against a backdrop of material operational deterioration: the company posted -$2.3M net income for its most recent full fiscal year, annual revenue declined -36.0%, and the stock has fallen -35.9% from its 52-week high of $15.22. At his prior MED purchase on 2025-06-13, the stock subsequently delivered a +9.7% 30-day return and +6.0% 90-day return, demonstrating one instance of favorable timing at this ticker. However, his current buy at $10.11 is positioned 4% above the 52-week low of $9.53 and faces headwinds from ongoing unprofitability and significant revenue contraction that warrant investor scrutiny into whether fundamentals have stabilized.

Chairman Daniel Chard bought 381 MED shares at $13.13 amid -43.8% revenue decline and $-772.0K net loss.

Chard Daniel R purchased 381 shares for $5,002.53, a small incremental addition to his 149.7K share position. The purchase occurred at $13.13, roughly 2.7% below the current market price of $13.49, but the stock remains down -38.5% from its 52-week high of $21.93. The underlying business context is materially adverse: latest quarterly revenue stands at $115.7M against an annual revenue decline of -43.8% year-over-year, and the company posted a net loss of $-772.0K. The P/E of 71.00 reflects earnings pressure. This buy in a contracting business environment merits examination of whether public disclosures support the transaction rationale and whether further deterioration or turnaround signals are evident in subsequent filings.